Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday.
The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases, Roche said.
